

Clinical Policy: Siltuximab (Sylvant)

Reference Number: CP.PHAR.329

Effective Date: 03/17

Last Review Date: 03/17

[Coding Implications](#)
[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

The intent of these criteria is to ensure that patients follow selection elements established by Centene® clinical policy for siltuximab (Sylvant™).

Policy/Criteria

It is the policy of health plans affiliated with Centene Corporation® that Sylvant is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Castleman's Disease (must meet all):

1. Diagnosis of Castleman's disease* (CD, angiofollicular lymph node hyperplasia) confirmed by biopsy of involved tissue (usually a lymph node);
2. Meets a or b:
 - a. FDA approved use for treatment of multicentric** Castleman's disease (MCD);
 - b. NCCN recommended use for second-line, single-agent treatment of relapsed or refractory unicentric** Castleman's disease (UCD);
3. Meets the following parameters prior to treatment:
 - a. Human immunodeficiency virus (HIV) negative;
 - b. Human herpesvirus-8 (HHV-8) negative;
 - c. Absolute neutrophil count: $\geq 1.0 \times 10^9/L$;
 - d. Platelet count $\geq 75 \times 10^9/L$;
 - e. Hemoglobin < 17 g/dL.

*Group of lymphoproliferative disorders (classified under non-Hodgkin B-cell lymphomas) that share common histologic features.

**Multicentric CD (systemic disease with symptoms that may include generalized peripheral lymphadenopathy, hepatosplenomegaly, frequent fevers, night sweats); unicentric CD (localized disease that generally is asymptomatic).

Approval duration: 6 months

B. Other diagnoses/indications: Refer to CP.PHAR.57 – Global Biopharm Policy.

II. Continued Approval

A. Castleman's Disease (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met all initial approval criteria;
2. No disease progression or unacceptable toxicity;
3. Meets the following laboratory parameters:
 - a. Absolute neutrophil count: $\geq 1.0 \times 10^9/L$;

- b. Platelet count $\geq 50 \times 10^9/L$;
- c. Hemoglobin $< 17 \text{ g/dL}$.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

- 1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy; or
- 2. Refer to CP.PHAR.57 - Global Biopharm Policy.

Background

Description/Mechanism of Action:

Sylvant (siltuximab) is a human-mouse chimeric monoclonal antibody that binds human interleukin-6 (IL-6). Siltuximab binds human IL-6 and prevents the binding of IL-6 to both soluble and membrane bound IL-6 receptors. IL-6 has been shown to be involved in diverse normal physiologic processes such as induction of immunoglobulin secretion. Overproduction of IL-6 has been linked to systemic manifestations in patients with multicentric Castleman's disease (MCD).

Formulations:

Sylvant is packaged as a lyophilized powder for reconstitution in 100 mg or 400 mg single-use vials (reconstituted with Sterile Water for Injection to 20 mg/mL).

FDA Approved Indications:

Sylvant is an interleukin-6 (IL-6) antagonist/intravenous formulation indicated for:

- Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.

Limitation of use

- Sylvant was not studied in patients with MCD who are HIV positive or HHV-8 positive because Sylvant did not bind to virally produced IL-6 in a nonclinical study.

Appendices

Appendix A: Abbreviation Key

CD: Castleman's disease

HHV-8: negative and human herpesvirus-8

HIV: human immunodeficiency virus

MCD: multicentric Castleman's disease

UCD: unicentric Castleman's disease

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J2860	Injection, siltuximab, 10 mg

Reviews, Revisions, and Approvals	Date	Approval Date
Policy split from CP.PHAR.183 Excellus Other Specialty Pharmacy.	02/17	03/17

References

1. Sylvant prescribing information. Horsham, PA: Janssen Biotech, Inc.; November 2015. Available at <https://www.janssenmd.com/pdf/sylvant/SYLVANT-PI.pdf>. Accessed February 27, 2017.
2. Siltuximab. In: National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at www.NCCN.org. Accessed February 27, 2017.
3. Non-Hodgkin’s B-cell lymphomas (Version 2.2017). In: National Comprehensive Cancer Network Guidelines. Available at NCCN.org. Accessed February 27, 2017.
4. Aster JC, Brown JR, Munshi NC. Multicentric Castleman’s disease. In: UpToDate, Waltham, MA: Walters Kluwer Health; 2017. Available at www.UpToDate.com. Accessed February 27, 2017.
5. Brown JR, Aster, JC, Munshi NC. Unicentric Castleman’s disease. In: UpToDate, Waltham, MA: Walters Kluwer Health; 2017. Available at www.UpToDate.com. Accessed February 27, 2017.

Important reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and

regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

Note: For Medicare members, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare coverage articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.